Biotechnology

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS  (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deplo...

2026-08-04 18:15 1698

MGI Tech and NCSTAR Sign Memorandum of Understanding to Explore Bringing Multi-Omics Infrastructure under DCSP framework to Queensland's Spatial Biology Research

Collaboration, coordinated through NCSTAR at QIMR Berghofer, gives Queensland researchers a pathway to trial and validate MGI's integrated DCSP framework — spanning DNA genomics, cell omics, spatial omics and proteomics — locally, fast-tracking their translation into real-world research and futur...

2026-08-04 17:50 1813

Sisram Medical Powers Up China EBD Growth Engine with Flagship "黑金牛奶光" Launch

Driving Innovation and Proactive Empowerment to Unlock Localized Growth in China HONG KONG, Aug. 4, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices ("EBD"), injectables, and other complementary solutions, today un...

2026-08-04 17:37 3006

Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying Suite

* Piramal Pharma Solutions has added a new spray drying suite with Band 5 containment capacity at its dedicated peptide facility in Turbhe, India, equipped with its own air handling units, nitrogen supply, and control systems. * The new suite empowers Turbhe to support the formulation of chall...

2026-08-04 17:08 1719

Innogen Pharmaceuticals Receives PIC/S GMP Certificatation, Accelerating Global Expansion of Efsubaglutide Alfa

SHANGHAI, Aug. 4, 2026 /PRNewswire/ -- Innogen Pharmaceuticals (HK.2591), a biopharmaceutical company dedicated to innovative drug discovery and industrialization in metabolic diseases, today announced that its Efsubaglutide alfa manufacturing facility in Suzhou has officially passed a compliance...

2026-08-04 13:25 2557

Ainex's ENAD Chosen for Singapore's National University Hospital After Global Competition

* ENAD, Korea's First and Only AI-Assisted Solution Approved for Both Upper and Lower GI Endoscopy * ENAD Secures Singapore Hospital Adoption in Competition with Medtronic, Olympus, and Fujifilm * Rapid Market Breakthrough Follows Singapore HSA Approval; Joint Research to Drive Further AI P...

2026-08-04 08:00 2896

Gene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' Academy

At the Precision Oncology Academy 2026, leading international experts explored how insights from tumour DNA and RNA can reveal treatment opportunities, explain drug resistance, and translate into more confident treatment decisions to improve cancer care. KUALA LUMPUR, Malaysia, Aug. 4, 2026 /PRN...

2026-08-04 06:00 5499

Enzene Launches NeX™, a Comprehensive Suite of Solutionsto Enable Cost-Efficient, High-Yielding Local Biomanufacturing

PUNE, India, Aug. 4, 2026 /PRNewswire/ -- Enzene, a leading global continuously innovative development and manufacturing organization (CIDMO™), today announced the launch of NeX™, a transformative end-to-end partnership model that enables governments, institutions, and biopharma organizations to ...

2026-08-04 02:25 3384

KPJ Healthcare Launches First Orthopaedic and Rheumatology Centre of Excellence Under the KPJ Health System

BUKIT MERTAJAM, Malaysia, Aug. 4, 2026 /PRNewswire/ -- KPJ Healthcare Berhad ("KPJ Healthcare" or "the Group") today launched its first Orthopaedic and Rheumatology Centre of Excellence ("CoE") at KPJ Penang Specialist Hospital ("KPJ Penang"), marking the third CoE under the KPJ Health System ("K...

2026-08-04 00:06 3739

Human Longevity Makes Clinical-Grade Whole Genome Sequencing Available to All for $599

The same genomic technology once limited to specialist programs is now accessible to anyone, paired with an AI platform built on over a decade of clinical data and a new multimillion-dollar collaboration with Insilico Medicine to predict disease before it begins. SAN FRANCISCO, Aug. 3, 2026 /PRN...

2026-08-04 00:00 1973

Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination

-Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight across two pivotal trials in the U.S., Europe, and Canada. -Positive preclinical data in non-human primates announced for first-in-class once-da...

2026-08-03 18:55 2345

WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model

SHANGHAI, Aug. 3, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first half ending June 30, 2026 ("Reporting Period"). The Company...

2026-08-03 17:49 4160

New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS

* Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical Benefits Scheme (PBS) for adults with relapsed or refractory follicular lymphoma (R/R FL) ...

2026-08-02 22:01 3079

CLASSYS Appoints Former Samsung Electronics Executive Vice President Jun-oh Yoon as CEO to Lead Its Next Stage of Global Growth

* Former Samsung Group and Samsung Electronics executive who led corporate growth strategy and major global M&A initiatives across the Corporate Strategy Office and DX Division * Brings extensive global leadership experience in business strategy, operations, and value creation across robotics...

2026-07-31 23:12 11500

Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy

* RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world's first saRNA therapy for ocular diseases * RAG-1C utilizes Ractigen's clinically validated LiCO™ platform to target p21 gene activation for long-lasting anti-fi...

2026-07-31 19:00 4057

IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand

SHANGHAI, July 31, 2026 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT") (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the "Exclusive Partnership") with Pharmanovia, a global specialty pharmaceutical company which partners with innovative biotech and large pha...

2026-07-31 15:48 2308

CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial

HANGZHOU, China, July 31, 2026 /PRNewswire/ -- CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in both research and strategic partnership. At the 2026 ASCO Annual Meeting, CellOrigin's scientific co...

2026-07-31 14:15 2288

Telix H1 2026 Results: Investor Webcast Notification

MELBOURNE, Australia and INDIANAPOLIS, July 31, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will release its financial results for the half-year ended June 30, 2026 on Thursday August 20, 2026. An investor webcast and conference call ...

2026-07-31 06:41 2317

HKEY-AI2Vivo™ 1.0: HKeyBio Accelerates In Vivo Translation for AI-Designed Candidates

HKEY-AI2Vivo™ 1.0 supports the move from computational hypotheses to in vivo translational evidence in autoimmune and allergy research BOSTON and SUZHOU, China, July 30, 2026 /PRNewswire/ -- HKeyBio has establishedHKEY-AI2Vivo™ 1.0, its AI Candidate In Vivo Validation Acceleration Program. The p...

2026-07-30 21:06 1893

Insilico Medicine Launches the Industry's First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science

Leveraging 30+ validated PCC programs and over 12 years of model development experience to create a large-scale real-world "blind test" for frontier AI and foundation models, with a transparent public leaderboard. CAMBRIDGE, Mass., July 30, 2026 /PRNewswire/ -- As general-purpose and domain-spec...

2026-07-30 21:00 2088
12345 ... 352

Week's Top Stories